Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–42. https://doi.org/10.1002/cncr.22570.
Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95–120. https://doi.org/10.1016/S0145-2126(02)00098-X.
Collin M. Haematopoietic and immune defects associated with GATA2 mutation. Pathology. 2018;50:S44. https://doi.org/10.1016/j.pathol.2017.12.104.
Zhang W, Shao Z, Fu R, Wang H, Li L, Liu H. Down-regulation of TET2 in CD3+ and CD34+ cells of myelodysplastic syndromes and enhances CD34+ cells proliferation. Int J Clin Exper Pathol. 2015;8(9):10840.
Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res. 2001;25:1075–83. https://doi.org/10.1016/S0145-2126(01)00083-2.
Article CAS PubMed Google Scholar
Wlodarski MW, O’Keefe C, Howe EC, Risitano AM, Rodriguez A, Warshawsky I, Loughran TP Jr, Maciejewski JP. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood. 2005;106:2769–80. https://doi.org/10.1182/blood-2004-10-4045.
Article CAS PubMed Google Scholar
Fozza C, Dore F, Isoni MA, Crobu V. The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol. 2016. https://doi.org/10.1016/j.critrevonc.2016.08.016.
Lambert C, Wu Y, Aanei C. Bone marrow immunity and myelodysplasia. Front Oncol. 2016;6:172. https://doi.org/10.3389/fonc.2016.00172.
Article PubMed PubMed Central Google Scholar
Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology. 2002;2002:136–61. https://doi.org/10.1182/asheducation-2002.1.136.
Kerndrup G, Meyer K, Ellegaard J, Hokland P. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leukemia research. 1984. https://doi.org/10.1016/0145-2126(84)90147-4.
Porzsolt F, Heimpel H. Impaired T-cell and NK-cell function in patients with preleukemia. Blut. 1982. https://doi.org/10.1007/BF00320191.
Anderson RW, Volsky DJ, Greenberg B, Knox SJ, Bechtold T, Kuszynski C, Harada S, Purtilo DT. Lymphocyte abnormalities in preleukemia–I. decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leukemia Res. 1983. https://doi.org/10.1016/0145-2126(83)90103-0.
Lanier LL. NK cell recognition. Annual Rev Immunol. 2005;23(1):225–74.
Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573–81. https://doi.org/10.1016/S1074-7613(00)70060-4.
Article CAS PubMed Google Scholar
Wagner AK, Kadri N, Snall J, Brodin P, Gilfillan S, Colonna M, Bernhardt G, Hoglund P, Karre K, Chambers BJ. Expression of CD226 is associated to but not required for NK cell education. Nat Commun. 2017;8:15627. https://doi.org/10.1038/ncomms15627.
Article CAS PubMed PubMed Central Google Scholar
Borrego F, Kabat J, Kim D-K, Lieto L, Maasho K, Peña J, Solana R, Coligan JE. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol. 2002;38:637–60. https://doi.org/10.1016/S0161-5890(01)00107-9.
Article CAS PubMed Google Scholar
Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nature Immunol. 2018. https://doi.org/10.1038/s41590-018-0132-0.
Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38:20–8. https://doi.org/10.1016/j.it.2016.10.002.
Article CAS PubMed Google Scholar
Liu X-G, Hou M, Liu Y. TIGIT, a novel therapeutic target for tumor immunotherapy. Immunol Invest. 2017;46:172–82. https://doi.org/10.1080/08820139.2016.1237524.
Article CAS PubMed Google Scholar
Li M, Xia P, Du Y, Liu S, Huang G, Chen J, Zhang H, Hou N, Cheng X, Zhou L, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J Biol Chem. 2014;289:17647–57. https://doi.org/10.1074/jbc.M114.572420.
Article CAS PubMed PubMed Central Google Scholar
Liu S, Zhang H, Li M, Hu D, Li C, Ge B, Jin B, Fan Z. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20:456–64. https://doi.org/10.1038/cdd.2012.141.
Article CAS PubMed Google Scholar
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nature Immunol. 2009;10:48–57. https://doi.org/10.1038/ni.1674.
Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proceed Nat Acad Sci. 2009. https://doi.org/10.1073/pnas.0903474106.
Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A, Honda SI, Lanier LL, Shibuya A. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol. 2004. https://doi.org/10.1093/intimm/dxh059.
Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR, Becker PS. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J. 2015;5: e302. https://doi.org/10.1038/bcj.2015.17.
Article CAS PubMed PubMed Central Google Scholar
Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL, Lian Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7: e2062. https://doi.org/10.1038/cddis.2015.327.
Article CAS PubMed PubMed Central Google Scholar
Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107:1484–90. https://doi.org/10.1182/blood-2005-07-2775.
Article CAS PubMed Google Scholar
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006. https://doi.org/10.1634/stemcells.2004-0359.
Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leuk Lymphoma. 2011;52:2045–9. https://doi.org/10.3109/10428194.2011.584002.
Article CAS PubMed Google Scholar
Yang L, Qian Y, Eksioglu E, Epling-Burnette PK, Wei S. The inflammatory microenvironment in MDS. Cell Mol Life Sci. 2015;72:1959–66. https://doi.org/10.1007/s00018-015-1846-x.
Article CAS PubMed Google Scholar
Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Current Opin Cell Biol. 2004. https://doi.org/10.1016/j.ceb.2004.07.007.
Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723–32. https://doi.org/10.1038/s41590-018-0132-0.
Article CAS PubMed Google Scholar
Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol. 2017. https://doi.org/10.1007/s00262-017-2031-x.
Xu SJ, Shao ZH, Fu R, Wang HQ, Liu H, Liu CY, Zhang W. Subtype and functional biomarker changes of NK cells in peripheral blood of patients with myelodysplastic syndrome. Zhongguo shi yan xue ye xue za zhi. 2017. https://doi.org/10.7534/j.issn.1009-2137.2017.03.036.
Iwase O, Aizawa S, Kuriyama Y, Yaguchi M, Nakano M, Toyama K. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. Ann Hematol. 1995;71:293–9. https://doi.org/10.1007/BF01697982.
Article CAS PubMed Google Scholar
Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, et al. DNAM-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers. 2019;11:877. https://doi.org/10.3390/cancers11060877.
Article CAS PubMed Central Google Scholar
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895–699895. https://doi.org/10.3389/fimmu.2021.699895.
留言 (0)